 | • レポートコード：QFJ1-5669 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、代償性肝硬変タイプCの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（拮抗薬、抗ウイルス薬、コルチコステロイド、キレート剤）、用途別市場規模（小売薬局、病院薬局、オンライン薬局、ドラッグストア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・代償性肝硬変タイプCの市場動向 ・企業の競争状況、市場シェア ・代償性肝硬変タイプCの種類別市場規模と予測2016-2027（拮抗薬、抗ウイルス薬、コルチコステロイド、キレート剤） ・代償性肝硬変タイプCの用途別市場規模と予測2016-2027（小売薬局、病院薬局、オンライン薬局、ドラッグストア） ・代償性肝硬変タイプCの北米市場規模2016-2027（アメリカ、カナダ） ・代償性肝硬変タイプCの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・代償性肝硬変タイプCのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・代償性肝硬変タイプCの中南米市場規模2016-2027（メキシコ、ブラジル） ・代償性肝硬変タイプCの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Gilead Sciences, Inc.、AbbVie Inc.、Novartis International AG、Intercept Pharmaceuticals, Inc.、Novo Nordisk A/S、Eli Lilly and Company、Alnylam Pharmaceuticals Inc.、Cadila Healthcare Ltd、Sanofi S.A、Pfizer Inc.、Sun Pharmaceutical Industries Limited） ・結論 |
Cirrhosis is scarring or fibrosis of the liver caused due to many types of liver diseases like chronic alcoholism and hepatitis. The liver carries out several functions, including detoxification of harmful substances body, cleaning the blood and making of the vital nutrients. Cirrhosis occurs in response to damage caused to your liver. Most common causes of Compensated liver cirrhosis are hepatitis B and C, diseases related to alcohol and NASH. Many chronic liver diseases develop gradually over time. The rate of progression of cirrhosis is usually slow in the early phases of the disease and then it accelerates after complications of cirrhosis arise. For the diagnosis of cirrhosis, liver biopsy is often required which provides information regarding the severity of the disease. Transient elastography (fibroscan) is a cost-effective technique for the screening of liver cirrhosis. Treatment for compensated cirrhosis should include treatment for HCV infection and can be treated by using direct antiviral agents. Diagnosis can be done by using esophagogastroduodenoscopy (EGD).
Market Analysis and Insights: Global Compensated Cirrhosis Type C Market
The global Compensated Cirrhosis Type C market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Compensated Cirrhosis Type C market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Compensated Cirrhosis Type C market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Compensated Cirrhosis Type C market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Compensated Cirrhosis Type C market.
Global Compensated Cirrhosis Type C Scope and Market Size
Compensated Cirrhosis Type C market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Compensated Cirrhosis Type C market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antagonist
Antiviral Drugs
Corticosteroids
Chelating Agents
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Drug Store
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Gilead Sciences, Inc.
AbbVie Inc.
Novartis International AG
Intercept Pharmaceuticals, Inc.
Novo Nordisk A/S
Eli Lilly and Company
Alnylam Pharmaceuticals Inc.
Cadila Healthcare Ltd
Sanofi S.A
Pfizer Inc.
Sun Pharmaceutical Industries Limited
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Compensated Cirrhosis Type C Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antagonist
1.2.3 Antiviral Drugs
1.2.4 Corticosteroids
1.2.5 Chelating Agents
1.3 Market by Application
1.3.1 Global Compensated Cirrhosis Type C Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.3.5 Drug Store
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Compensated Cirrhosis Type C Market Perspective (2016-2027)
2.2 Compensated Cirrhosis Type C Growth Trends by Regions
2.2.1 Compensated Cirrhosis Type C Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Compensated Cirrhosis Type C Historic Market Share by Regions (2016-2021)
2.2.3 Compensated Cirrhosis Type C Forecasted Market Size by Regions (2022-2027)
2.3 Compensated Cirrhosis Type C Industry Dynamic
2.3.1 Compensated Cirrhosis Type C Market Trends
2.3.2 Compensated Cirrhosis Type C Market Drivers
2.3.3 Compensated Cirrhosis Type C Market Challenges
2.3.4 Compensated Cirrhosis Type C Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Compensated Cirrhosis Type C Players by Revenue
3.1.1 Global Top Compensated Cirrhosis Type C Players by Revenue (2016-2021)
3.1.2 Global Compensated Cirrhosis Type C Revenue Market Share by Players (2016-2021)
3.2 Global Compensated Cirrhosis Type C Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Compensated Cirrhosis Type C Revenue
3.4 Global Compensated Cirrhosis Type C Market Concentration Ratio
3.4.1 Global Compensated Cirrhosis Type C Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Compensated Cirrhosis Type C Revenue in 2020
3.5 Compensated Cirrhosis Type C Key Players Head office and Area Served
3.6 Key Players Compensated Cirrhosis Type C Product Solution and Service
3.7 Date of Enter into Compensated Cirrhosis Type C Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Compensated Cirrhosis Type C Breakdown Data by Type
4.1 Global Compensated Cirrhosis Type C Historic Market Size by Type (2016-2021)
4.2 Global Compensated Cirrhosis Type C Forecasted Market Size by Type (2022-2027)
5 Compensated Cirrhosis Type C Breakdown Data by Application
5.1 Global Compensated Cirrhosis Type C Historic Market Size by Application (2016-2021)
5.2 Global Compensated Cirrhosis Type C Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Compensated Cirrhosis Type C Market Size (2016-2027)
6.2 North America Compensated Cirrhosis Type C Market Size by Type
6.2.1 North America Compensated Cirrhosis Type C Market Size by Type (2016-2021)
6.2.2 North America Compensated Cirrhosis Type C Market Size by Type (2022-2027)
6.2.3 North America Compensated Cirrhosis Type C Market Size by Type (2016-2027)
6.3 North America Compensated Cirrhosis Type C Market Size by Application
6.3.1 North America Compensated Cirrhosis Type C Market Size by Application (2016-2021)
6.3.2 North America Compensated Cirrhosis Type C Market Size by Application (2022-2027)
6.3.3 North America Compensated Cirrhosis Type C Market Size by Application (2016-2027)
6.4 North America Compensated Cirrhosis Type C Market Size by Country
6.4.1 North America Compensated Cirrhosis Type C Market Size by Country (2016-2021)
6.4.2 North America Compensated Cirrhosis Type C Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Compensated Cirrhosis Type C Market Size (2016-2027)
7.2 Europe Compensated Cirrhosis Type C Market Size by Type
7.2.1 Europe Compensated Cirrhosis Type C Market Size by Type (2016-2021)
7.2.2 Europe Compensated Cirrhosis Type C Market Size by Type (2022-2027)
7.2.3 Europe Compensated Cirrhosis Type C Market Size by Type (2016-2027)
7.3 Europe Compensated Cirrhosis Type C Market Size by Application
7.3.1 Europe Compensated Cirrhosis Type C Market Size by Application (2016-2021)
7.3.2 Europe Compensated Cirrhosis Type C Market Size by Application (2022-2027)
7.3.3 Europe Compensated Cirrhosis Type C Market Size by Application (2016-2027)
7.4 Europe Compensated Cirrhosis Type C Market Size by Country
7.4.1 Europe Compensated Cirrhosis Type C Market Size by Country (2016-2021)
7.4.2 Europe Compensated Cirrhosis Type C Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Compensated Cirrhosis Type C Market Size (2016-2027)
8.2 Asia-Pacific Compensated Cirrhosis Type C Market Size by Type
8.2.1 Asia-Pacific Compensated Cirrhosis Type C Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Compensated Cirrhosis Type C Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Compensated Cirrhosis Type C Market Size by Type (2016-2027)
8.3 Asia-Pacific Compensated Cirrhosis Type C Market Size by Application
8.3.1 Asia-Pacific Compensated Cirrhosis Type C Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Compensated Cirrhosis Type C Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Compensated Cirrhosis Type C Market Size by Application (2016-2027)
8.4 Asia-Pacific Compensated Cirrhosis Type C Market Size by Region
8.4.1 Asia-Pacific Compensated Cirrhosis Type C Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Compensated Cirrhosis Type C Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Compensated Cirrhosis Type C Market Size (2016-2027)
9.2 Latin America Compensated Cirrhosis Type C Market Size by Type
9.2.1 Latin America Compensated Cirrhosis Type C Market Size by Type (2016-2021)
9.2.2 Latin America Compensated Cirrhosis Type C Market Size by Type (2022-2027)
9.2.3 Latin America Compensated Cirrhosis Type C Market Size by Type (2016-2027)
9.3 Latin America Compensated Cirrhosis Type C Market Size by Application
9.3.1 Latin America Compensated Cirrhosis Type C Market Size by Application (2016-2021)
9.3.2 Latin America Compensated Cirrhosis Type C Market Size by Application (2022-2027)
9.3.3 Latin America Compensated Cirrhosis Type C Market Size by Application (2016-2027)
9.4 Latin America Compensated Cirrhosis Type C Market Size by Country
9.4.1 Latin America Compensated Cirrhosis Type C Market Size by Country (2016-2021)
9.4.2 Latin America Compensated Cirrhosis Type C Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Compensated Cirrhosis Type C Market Size (2016-2027)
10.2 Middle East & Africa Compensated Cirrhosis Type C Market Size by Type
10.2.1 Middle East & Africa Compensated Cirrhosis Type C Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Compensated Cirrhosis Type C Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Compensated Cirrhosis Type C Market Size by Type (2016-2027)
10.3 Middle East & Africa Compensated Cirrhosis Type C Market Size by Application
10.3.1 Middle East & Africa Compensated Cirrhosis Type C Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Compensated Cirrhosis Type C Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Compensated Cirrhosis Type C Market Size by Application (2016-2027)
10.4 Middle East & Africa Compensated Cirrhosis Type C Market Size by Country
10.4.1 Middle East & Africa Compensated Cirrhosis Type C Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Compensated Cirrhosis Type C Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Gilead Sciences, Inc.
11.1.1 Gilead Sciences, Inc. Company Details
11.1.2 Gilead Sciences, Inc. Business Overview
11.1.3 Gilead Sciences, Inc. Compensated Cirrhosis Type C Introduction
11.1.4 Gilead Sciences, Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.1.5 Gilead Sciences, Inc. Recent Development
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Details
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Compensated Cirrhosis Type C Introduction
11.2.4 AbbVie Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.2.5 AbbVie Inc. Recent Development
11.3 Novartis International AG
11.3.1 Novartis International AG Company Details
11.3.2 Novartis International AG Business Overview
11.3.3 Novartis International AG Compensated Cirrhosis Type C Introduction
11.3.4 Novartis International AG Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.3.5 Novartis International AG Recent Development
11.4 Intercept Pharmaceuticals, Inc.
11.4.1 Intercept Pharmaceuticals, Inc. Company Details
11.4.2 Intercept Pharmaceuticals, Inc. Business Overview
11.4.3 Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Introduction
11.4.4 Intercept Pharmaceuticals, Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.4.5 Intercept Pharmaceuticals, Inc. Recent Development
11.5 Novo Nordisk A/S
11.5.1 Novo Nordisk A/S Company Details
11.5.2 Novo Nordisk A/S Business Overview
11.5.3 Novo Nordisk A/S Compensated Cirrhosis Type C Introduction
11.5.4 Novo Nordisk A/S Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.5.5 Novo Nordisk A/S Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Compensated Cirrhosis Type C Introduction
11.6.4 Eli Lilly and Company Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.6.5 Eli Lilly and Company Recent Development
11.7 Alnylam Pharmaceuticals Inc.
11.7.1 Alnylam Pharmaceuticals Inc. Company Details
11.7.2 Alnylam Pharmaceuticals Inc. Business Overview
11.7.3 Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Introduction
11.7.4 Alnylam Pharmaceuticals Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.7.5 Alnylam Pharmaceuticals Inc. Recent Development
11.8 Cadila Healthcare Ltd
11.8.1 Cadila Healthcare Ltd Company Details
11.8.2 Cadila Healthcare Ltd Business Overview
11.8.3 Cadila Healthcare Ltd Compensated Cirrhosis Type C Introduction
11.8.4 Cadila Healthcare Ltd Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.8.5 Cadila Healthcare Ltd Recent Development
11.9 Sanofi S.A
11.9.1 Sanofi S.A Company Details
11.9.2 Sanofi S.A Business Overview
11.9.3 Sanofi S.A Compensated Cirrhosis Type C Introduction
11.9.4 Sanofi S.A Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.9.5 Sanofi S.A Recent Development
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Company Details
11.10.2 Pfizer Inc. Business Overview
11.10.3 Pfizer Inc. Compensated Cirrhosis Type C Introduction
11.10.4 Pfizer Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.10.5 Pfizer Inc. Recent Development
11.11 Sun Pharmaceutical Industries Limited
11.11.1 Sun Pharmaceutical Industries Limited Company Details
11.11.2 Sun Pharmaceutical Industries Limited Business Overview
11.11.3 Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Introduction
11.11.4 Sun Pharmaceutical Industries Limited Revenue in Compensated Cirrhosis Type C Business (2016-2021)
11.11.5 Sun Pharmaceutical Industries Limited Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Compensated Cirrhosis Type C Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antagonist
Table 3. Key Players of Antiviral Drugs
Table 4. Key Players of Corticosteroids
Table 5. Key Players of Chelating Agents
Table 6. Global Compensated Cirrhosis Type C Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Compensated Cirrhosis Type C Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Compensated Cirrhosis Type C Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Compensated Cirrhosis Type C Market Share by Regions (2016-2021)
Table 10. Global Compensated Cirrhosis Type C Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Compensated Cirrhosis Type C Market Share by Regions (2022-2027)
Table 12. Compensated Cirrhosis Type C Market Trends
Table 13. Compensated Cirrhosis Type C Market Drivers
Table 14. Compensated Cirrhosis Type C Market Challenges
Table 15. Compensated Cirrhosis Type C Market Restraints
Table 16. Global Compensated Cirrhosis Type C Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Compensated Cirrhosis Type C Market Share by Players (2016-2021)
Table 18. Global Top Compensated Cirrhosis Type C Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Compensated Cirrhosis Type C as of 2020)
Table 19. Ranking of Global Top Compensated Cirrhosis Type C Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Compensated Cirrhosis Type C Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Compensated Cirrhosis Type C Product Solution and Service
Table 23. Date of Enter into Compensated Cirrhosis Type C Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Compensated Cirrhosis Type C Revenue Market Share by Type (2016-2021)
Table 27. Global Compensated Cirrhosis Type C Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Compensated Cirrhosis Type C Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Compensated Cirrhosis Type C Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Compensated Cirrhosis Type C Revenue Market Share by Application (2016-2021)
Table 31. Global Compensated Cirrhosis Type C Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Compensated Cirrhosis Type C Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Compensated Cirrhosis Type C Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Compensated Cirrhosis Type C Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Compensated Cirrhosis Type C Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Compensated Cirrhosis Type C Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Compensated Cirrhosis Type C Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Compensated Cirrhosis Type C Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Compensated Cirrhosis Type C Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Compensated Cirrhosis Type C Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Compensated Cirrhosis Type C Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Compensated Cirrhosis Type C Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Compensated Cirrhosis Type C Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Compensated Cirrhosis Type C Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Compensated Cirrhosis Type C Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Compensated Cirrhosis Type C Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Compensated Cirrhosis Type C Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Compensated Cirrhosis Type C Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Compensated Cirrhosis Type C Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Compensated Cirrhosis Type C Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Compensated Cirrhosis Type C Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Compensated Cirrhosis Type C Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Compensated Cirrhosis Type C Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Compensated Cirrhosis Type C Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Compensated Cirrhosis Type C Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Compensated Cirrhosis Type C Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Compensated Cirrhosis Type C Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Compensated Cirrhosis Type C Market Size by Country (2022-2027) & (US$ Million)
Table 63. Gilead Sciences, Inc. Company Details
Table 64. Gilead Sciences, Inc. Business Overview
Table 65. Gilead Sciences, Inc. Compensated Cirrhosis Type C Product
Table 66. Gilead Sciences, Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 67. Gilead Sciences, Inc. Recent Development
Table 68. AbbVie Inc. Company Details
Table 69. AbbVie Inc. Business Overview
Table 70. AbbVie Inc. Compensated Cirrhosis Type C Product
Table 71. AbbVie Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 72. AbbVie Inc. Recent Development
Table 73. Novartis International AG Company Details
Table 74. Novartis International AG Business Overview
Table 75. Novartis International AG Compensated Cirrhosis Type C Product
Table 76. Novartis International AG Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 77. Novartis International AG Recent Development
Table 78. Intercept Pharmaceuticals, Inc. Company Details
Table 79. Intercept Pharmaceuticals, Inc. Business Overview
Table 80. Intercept Pharmaceuticals, Inc. Compensated Cirrhosis Type C Product
Table 81. Intercept Pharmaceuticals, Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 82. Intercept Pharmaceuticals, Inc. Recent Development
Table 83. Novo Nordisk A/S Company Details
Table 84. Novo Nordisk A/S Business Overview
Table 85. Novo Nordisk A/S Compensated Cirrhosis Type C Product
Table 86. Novo Nordisk A/S Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 87. Novo Nordisk A/S Recent Development
Table 88. Eli Lilly and Company Company Details
Table 89. Eli Lilly and Company Business Overview
Table 90. Eli Lilly and Company Compensated Cirrhosis Type C Product
Table 91. Eli Lilly and Company Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 92. Eli Lilly and Company Recent Development
Table 93. Alnylam Pharmaceuticals Inc. Company Details
Table 94. Alnylam Pharmaceuticals Inc. Business Overview
Table 95. Alnylam Pharmaceuticals Inc. Compensated Cirrhosis Type C Product
Table 96. Alnylam Pharmaceuticals Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 97. Alnylam Pharmaceuticals Inc. Recent Development
Table 98. Cadila Healthcare Ltd Company Details
Table 99. Cadila Healthcare Ltd Business Overview
Table 100. Cadila Healthcare Ltd Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 101. Cadila Healthcare Ltd Recent Development
Table 102. Sanofi S.A Company Details
Table 103. Sanofi S.A Business Overview
Table 104. Sanofi S.A Compensated Cirrhosis Type C Product
Table 105. Sanofi S.A Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 106. Sanofi S.A Recent Development
Table 107. Pfizer Inc. Company Details
Table 108. Pfizer Inc. Business Overview
Table 109. Pfizer Inc. Compensated Cirrhosis Type C Product
Table 110. Pfizer Inc. Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 111. Pfizer Inc. Recent Development
Table 112. Sun Pharmaceutical Industries Limited Company Details
Table 113. Sun Pharmaceutical Industries Limited Business Overview
Table 114. Sun Pharmaceutical Industries Limited Compensated Cirrhosis Type C Product
Table 115. Sun Pharmaceutical Industries Limited Revenue in Compensated Cirrhosis Type C Business (2016-2021) & (US$ Million)
Table 116. Sun Pharmaceutical Industries Limited Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Compensated Cirrhosis Type C Market Share by Type: 2020 VS 2027
Figure 2. Antagonist Features
Figure 3. Antiviral Drugs Features
Figure 4. Corticosteroids Features
Figure 5. Chelating Agents Features
Figure 6. Global Compensated Cirrhosis Type C Market Share by Application: 2020 VS 2027
Figure 7. Retail Pharmacy Case Studies
Figure 8. Hospital Pharmacy Case Studies
Figure 9. Online Pharmacy Case Studies
Figure 10. Drug Store Case Studies
Figure 11. Compensated Cirrhosis Type C Report Years Considered
Figure 12. Global Compensated Cirrhosis Type C Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Compensated Cirrhosis Type C Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Compensated Cirrhosis Type C Market Share by Regions: 2020 VS 2027
Figure 15. Global Compensated Cirrhosis Type C Market Share by Regions (2022-2027)
Figure 16. Global Compensated Cirrhosis Type C Market Share by Players in 2020
Figure 17. Global Top Compensated Cirrhosis Type C Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Compensated Cirrhosis Type C as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Compensated Cirrhosis Type C Revenue in 2020
Figure 19. Global Compensated Cirrhosis Type C Revenue Market Share by Type (2016-2021)
Figure 20. Global Compensated Cirrhosis Type C Revenue Market Share by Type (2022-2027)
Figure 21. North America Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Compensated Cirrhosis Type C Market Share by Type (2016-2027)
Figure 23. North America Compensated Cirrhosis Type C Market Share by Application (2016-2027)
Figure 24. North America Compensated Cirrhosis Type C Market Share by Country (2016-2027)
Figure 25. United States Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Compensated Cirrhosis Type C Market Share by Type (2016-2027)
Figure 29. Europe Compensated Cirrhosis Type C Market Share by Application (2016-2027)
Figure 30. Europe Compensated Cirrhosis Type C Market Share by Country (2016-2027)
Figure 31. Germany Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Compensated Cirrhosis Type C Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Compensated Cirrhosis Type C Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Compensated Cirrhosis Type C Market Share by Region (2016-2027)
Figure 41. China Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Compensated Cirrhosis Type C Market Share by Type (2016-2027)
Figure 49. Latin America Compensated Cirrhosis Type C Market Share by Application (2016-2027)
Figure 50. Latin America Compensated Cirrhosis Type C Market Share by Country (2016-2027)
Figure 51. Mexico Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Compensated Cirrhosis Type C Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Compensated Cirrhosis Type C Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Compensated Cirrhosis Type C Market Share by Country (2016-2027)
Figure 57. Turkey Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Compensated Cirrhosis Type C Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Gilead Sciences, Inc. Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 61. AbbVie Inc. Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 62. Novartis International AG Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 63. Intercept Pharmaceuticals, Inc. Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 64. Novo Nordisk A/S Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 66. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 67. Cadila Healthcare Ltd Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 68. Sanofi S.A Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 69. Pfizer Inc. Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 70. Sun Pharmaceutical Industries Limited Revenue Growth Rate in Compensated Cirrhosis Type C Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
世界の小売薬局市場規模・現状・予測（2021年-2027年） A retail pharmacy refers to a retail store of medicines. Market Analysis and Insights: Global Retail Pharmacy Market The global Retail Pharmacy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in…- 世界のペット専用医薬品市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Pet Speciality Drugs Market The global Pet Speciality Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report m…
- 原発性胆汁性肝硬変薬のグローバル市場調査 2019年 The global Primary Biliary Cirrhosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Primary Biliary Cirrhosis Drug volume and value at global level, regional level and company level. From a gl…
- 原発性胆汁性肝硬変薬のグローバル市場調査 2019年 The global Primary Biliary Cirrhosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Primary Biliary Cirrhosis Drug volume and value at global level, regional level and company level. From a gl…
- 世界の抗コリン薬市場規模・現状・予測（2021年-2027年） Anticholinergic drugs are used to restrict the acetylcholine-provoked neurotransmission in different parts of the body including heart, peripheral nervous system, and other parts. Acetylcholine controls the involuntary functions such as salivation, sweating, digestion, and several others. The drug i…